← SWS Hemodialysis Care Co. Ltd. A overview

SWS Hemodialysis Care Co. Ltd. A vs Imeik Technology Development: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

SWS Hemodialysis Care Co. Ltd. A (688410.CG)

Q3 202622 Jul – 28 Aug 2026

▲3▼1

Strong H1 profit and new product approvals offset major shareholder selling

H1 profit jumps 71% on higher sales and margins SWS reported first-half 2026 revenue up 29.8% to 464 million yuan and net profit up 71.46% to 94.37 million yuan. Higher sales of self-made blood purification consumables and better gross margin drove the gain, showing the core business is growing profitably.
This is the main positive force behind the stock, showing strong underlying business momentum.
New product approvals expand market access A subsidiary received a medical device registration certificate for single-use hemodialysis blood tubing and a change filing for continuous blood purification tubing. These approvals let SWS sell more products in hospitals, supporting future revenue growth.
New product approvals are a concrete growth driver that can lift future sales and investor confidence.
High dividend payout signals confidence and cash returns SWS plans to pay 2 yuan per 10 shares, a 94.83% payout of first-half profit. A high dividend returns cash to shareholders and signals management's confidence in steady earnings, which can attract income-focused investors.
The dividend is a new capital return event that supports the stock's appeal and shows financial health.
Major shareholder plans to sell up to 4.03% stake A major shareholder plans to cut its stake by up to 4.03%, worth about 200 million yuan, starting September 3. This is the third reduction plan in a year, which can pressure the stock price by increasing the number of shares for sale.
This is the main counterweight to the positive news, explaining why the stock may face selling pressure.

August 202622 Jul – 28 Aug 2026

▲3▼1

Strong H1 profit and new product approvals offset major shareholder selling

H1 profit jumps 71% on higher sales and margins SWS reported first-half 2026 revenue up 29.8% to 464 million yuan and net profit up 71.46% to 94.37 million yuan. Higher sales of self-made blood purification consumables and better gross margin drove the gain, showing the core business is growing profitably.
This is the main positive force behind the stock, showing strong underlying business momentum.
New product approvals expand market access A subsidiary received a medical device registration certificate for single-use hemodialysis blood tubing and a change filing for continuous blood purification tubing. These approvals let SWS sell more products in hospitals, supporting future revenue growth.
New product approvals are a concrete growth driver that can lift future sales and investor confidence.
High dividend payout signals confidence and cash returns SWS plans to pay 2 yuan per 10 shares, a 94.83% payout of first-half profit. A high dividend returns cash to shareholders and signals management's confidence in steady earnings, which can attract income-focused investors.
The dividend is a new capital return event that supports the stock's appeal and shows financial health.
Major shareholder plans to sell up to 4.03% stake A major shareholder plans to cut its stake by up to 4.03%, worth about 200 million yuan, starting September 3. This is the third reduction plan in a year, which can pressure the stock price by increasing the number of shares for sale.
This is the main counterweight to the positive news, explaining why the stock may face selling pressure.

Latest22 Jul – 28 Aug 2026

▲3▼1

Strong H1 profit and new product approvals offset major shareholder selling

H1 profit jumps 71% on higher sales and margins SWS reported first-half 2026 revenue up 29.8% to 464 million yuan and net profit up 71.46% to 94.37 million yuan. Higher sales of self-made blood purification consumables and better gross margin drove the gain, showing the core business is growing profitably.
This is the main positive force behind the stock, showing strong underlying business momentum.
New product approvals expand market access A subsidiary received a medical device registration certificate for single-use hemodialysis blood tubing and a change filing for continuous blood purification tubing. These approvals let SWS sell more products in hospitals, supporting future revenue growth.
New product approvals are a concrete growth driver that can lift future sales and investor confidence.
High dividend payout signals confidence and cash returns SWS plans to pay 2 yuan per 10 shares, a 94.83% payout of first-half profit. A high dividend returns cash to shareholders and signals management's confidence in steady earnings, which can attract income-focused investors.
The dividend is a new capital return event that supports the stock's appeal and shows financial health.
Major shareholder plans to sell up to 4.03% stake A major shareholder plans to cut its stake by up to 4.03%, worth about 200 million yuan, starting September 3. This is the third reduction plan in a year, which can pressure the stock price by increasing the number of shares for sale.
This is the main counterweight to the positive news, explaining why the stock may face selling pressure.

Imeik Technology Development Co (300896.CS)

Q3 202615 Jul – 28 Sep 2026

▼3▲1

Imeik profit slumps as costs surge; new product approvals offer offset

First-half profit and sales both fell sharply Imeik's first-half revenue fell 6.42% to 1.216 billion yuan and net profit dropped 24.84% to 593 million yuan. Selling expenses jumped 63%, squeezing margins. Core injectable products shrank, so the market sees weaker earnings power and marks the stock down.
The half-year earnings miss is the main force weighing on the stock this period.
Goodwill risk from the REGEN acquisition Goodwill of 1.641 billion yuan sits on the balance sheet, 1.305 billion of it from buying South Korea's REGEN. If that business underperforms, the company must write it down, which would hit reported profit again. This adds uncertainty on top of the earnings decline.
It is a concrete balance-sheet risk that can hurt future profit and investor confidence.
New product approvals broaden the product line Imeik won approval for a sodium hyaluronate gel medical device and, in September, a lidocaine-tetracaine numbing cream used in filler and laser procedures. These add sellable products and support future revenue, though they take time to contribute meaningfully.
Approvals are the clearest positive counterweight to the weak earnings.
Botulinum toxin still not launched Imeik said its botulinum toxin product is not yet on sale, with the sales team only doing pre-launch work. This delays a much-anticipated new growth driver, so expected future revenue from it keeps getting pushed out.
A delayed key product launch removes a hoped-for growth catalyst.

August 202615 Jul – 28 Sep 2026

▼3▲1

Imeik profit slumps as costs surge; new product approvals offer offset

First-half profit and sales both fell sharply Imeik's first-half revenue fell 6.42% to 1.216 billion yuan and net profit dropped 24.84% to 593 million yuan. Selling expenses jumped 63%, squeezing margins. Core injectable products shrank, so the market sees weaker earnings power and marks the stock down.
The half-year earnings miss is the main force weighing on the stock this period.
Goodwill risk from the REGEN acquisition Goodwill of 1.641 billion yuan sits on the balance sheet, 1.305 billion of it from buying South Korea's REGEN. If that business underperforms, the company must write it down, which would hit reported profit again. This adds uncertainty on top of the earnings decline.
It is a concrete balance-sheet risk that can hurt future profit and investor confidence.
New product approvals broaden the product line Imeik won approval for a sodium hyaluronate gel medical device and, in September, a lidocaine-tetracaine numbing cream used in filler and laser procedures. These add sellable products and support future revenue, though they take time to contribute meaningfully.
Approvals are the clearest positive counterweight to the weak earnings.
Botulinum toxin still not launched Imeik said its botulinum toxin product is not yet on sale, with the sales team only doing pre-launch work. This delays a much-anticipated new growth driver, so expected future revenue from it keeps getting pushed out.
A delayed key product launch removes a hoped-for growth catalyst.

Latest15 Jul – 28 Sep 2026

▼3▲1

Imeik profit slumps as costs surge; new product approvals offer offset

First-half profit and sales both fell sharply Imeik's first-half revenue fell 6.42% to 1.216 billion yuan and net profit dropped 24.84% to 593 million yuan. Selling expenses jumped 63%, squeezing margins. Core injectable products shrank, so the market sees weaker earnings power and marks the stock down.
The half-year earnings miss is the main force weighing on the stock this period.
Goodwill risk from the REGEN acquisition Goodwill of 1.641 billion yuan sits on the balance sheet, 1.305 billion of it from buying South Korea's REGEN. If that business underperforms, the company must write it down, which would hit reported profit again. This adds uncertainty on top of the earnings decline.
It is a concrete balance-sheet risk that can hurt future profit and investor confidence.
New product approvals broaden the product line Imeik won approval for a sodium hyaluronate gel medical device and, in September, a lidocaine-tetracaine numbing cream used in filler and laser procedures. These add sellable products and support future revenue, though they take time to contribute meaningfully.
Approvals are the clearest positive counterweight to the weak earnings.
Botulinum toxin still not launched Imeik said its botulinum toxin product is not yet on sale, with the sales team only doing pre-launch work. This delays a much-anticipated new growth driver, so expected future revenue from it keeps getting pushed out.
A delayed key product launch removes a hoped-for growth catalyst.